Company: MiRecule Inc.
Job title: CEO
MC-30, a Targeted MicroRNA Therapy Inhibiting RTK Signalling and Drug Resistance in Head and Neck Cancer 1:15 pm
miR-30-5p is a critical tumor suppressor in a subset of head and neck cancers targeting multiple receptor tyrosine kinase pathways Genetic loss is associated with increased recurrence and poor outcomes MC-30 a novel targeted therapy mimicking the natural miR-30 gene can reduce drug resistance and may extend progression-free survivalRead more
day: Day Two